Novel antibody suppresses primary tumor growth and spread of triple-negative breast cancer
Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows…
Global Virus Network outlines priorities as Marburg virus emerges in Ethiopia
The Global Virus Network (GVN), a coalition of leading human and animal virologists in more than 40 countries…
Experimental drug engasertib shows promise for treating inherited bleeding disorder
Hereditary hemorrhagic telangiectasia (HHT) is the second most common inherited bleeding disorder worldwide, affecting 1 in 3,800 persons.…
2 No-Brainer Healthcare Stocks to Buy Now
Pfizer’s acquisition of obesity drugmaker Metsera positions the pharmaceutical giant to compete in a market expected to reach…
New insights into glioblastoma survival linked to brain fluid dynamics
Glioblastoma-the most aggressive form of brain cancer-remains one of medicine’s biggest challenges. Despite surgery, radiotherapy, and chemotherapy, most…
TRIMTECH Therapeutics appoints Dr Mike Hutton to Scientific Advisory Board
TRIMTECH Therapeutics, a biotech company creating novel, small molecule therapeutics that selectively degrade protein aggregates, to combat neurodegenerative…
Collaborative effort advances next-generation therapies for pancreatic and GI cancers
Last year, researchers at the University of California, Riverside, developed a novel “molecular crowbar” strategy to degrade the oncogenic enzyme…
The caffeine conundrum in rapid depression treatments
Perhaps the most intriguing implication of recent breakthrough research lies in an unexpected connection: the most rigorous mechanistic…
New NIH grants fuel research in oral cancer treatment and pain relief
Researchers at the School of Dentistry at UT Health San Antonio, the academic health center of The University…
Redefining control in anaerobic microbiome workflows
In this interview, Sheela Muley, Product Manager at Molecular Devices, and Dr Sushmita Sudarshan, Application Scientist in Assay Development at Molecular Devices,…
Scripps Research professor wins $3.2 million grant to unravel the mysteries of type 1 diabetes
Luc Teyton, professor in the Department of Immunology and Microbiology at Scripps Research, has received a five-year, $3.2…
Elevara Medicines Raises $70 Million Series A to Advance
Co-led by Forbion and Sofinnova Partners, along with founding investor Monograph Capital, and Weatherden Innovative lead program, ELV001,…